Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 27, 2012

Eisai Gains Russian Approval of Epilepsy Drug Zonegran

  • Russia’s drug regulator approved Eisai’s epilepsy drug, Zonegran™ (zonisamide), marking its first entry into the Russian market. The firm has an exclusive license to develop, commercialize, and market Zonegran in Russia, the EU, U.S., and Asia, from Dainippon Sumitomo Pharma. Launch of Zonegran in Russia is projected before the end of Eisai’s 201 financial year (March 30, 2013). The drug is indicated as an adjunctive therapy for treating adult epilepsy patients with partial seizures.

    Eisai says it is committed to building a presence in the Russian market as part of its drive to be a player in the top 20 pharmaceutical market regions. The firm has submitted marketing authorization applications in Russia for a number of additional drugs, including the cancer drug Halaven® (eribulin) and epilepsy drug Fycompa® (perampanel).

    “Eisai has been successfully operating in Europe for more than 20 years and we are proud to be increasing access to key medicines in countries outside of this region,” comments Gary Hendler, president and CEO of Eisai’s Europe, Middle East, and Africa Business.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »